Skip to main content
. 2022 Nov 23;9:1041044. doi: 10.3389/fcvm.2022.1041044

Figure 5.

Figure 5

Meta-analysis and TSA results of blood lipid-related indicators in dorzagliatin vs. placebo in the treatment of T2DM. (A) Meta-analysis and TSA results of TG in dorzagliatin vs. placebo in the treatment of T2DM. (B) Meta-analysis and TSA results of TC in dorzagliatin vs. placebo in the treatment of T2DM. (C) Meta-analysis and TSA results of LDL-C in dorzagliatin vs. placebo in the treatment of T2DM. (D) Meta-analysis and TSA results of HDL-C in dorzagliatin vs. placebo in the treatment of T2DM.